- ￥1188
- AntibodySystem
- FHE03411
- France
- 2025年07月13日
- FCM
- Mouse
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Anti-Human CD80/B7-1 Antibody (IDEC-114), FITC
- 抗体英文名：
Anti-Human CD80/B7-1 Antibody (IDEC-114), FITC
- 浓度：
0.5 mg/ml
- 应用范围：
FCM
- 宿主：
Mouse
- 适应物种：
Human
- 保质期：
1 year
- 级别：
科研级
- 库存：
999
- 供应商：
AntibodySystem
- 克隆性：
Monoclonal
- 保存条件：
Store at 4°C for 12 months. Protect from light. Do not freeze.
- 亚型：
IgG1, lambda
- 规格：
100T
| 宿主 | Mouse |
| 偶联物 | FITC |
| 种属反应性 | Human |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. |
| 浓度 | 0.5 mg/ml |
| 克隆类型 | Monoclonal |
| 同种型 | IgG1, lambda |
| 应用 | FCM |
| 靶标 | CD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1 |
| 内毒素水平 | Please contact with the lab for this information. |
| 稳定性和存储 | Store at 4°C for 12 months. Protect from light. Do not freeze. |
| 克隆号 | IDEC-114 |
| 备注 | For research use only. |
Currently, AntibodySystem's product lines cover multiple research areas, including 48 types of viruses and superbugs, parasites, tumors, Alzheimer's disease, Parkinson's disease, hypersensitivity and allergic reactions, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Immunohistochemistry using Anti-Ganglioside Antibodies
supernatant containing antiganglioside mAb overnight at 4°C. The time of incubation may range from 30 min. to overnight as determined by experience. 5. Wash with 1% BSA in PBS 4 times. 6. Incubate in FITC-conjugated goat anti-mouse IgM F(ab
Anti-GFP/BrdU In Situ Immunostaining
Materials 24 well dishes Millicell 0.4 µm inserts (Millipore PICM01250) - coated with fibronectin Culture medium PBS Fixative: 4% paraformaldehyde in PBS (pH 7.6) Rabbit anti-GFP (Molecular Probes, A-11122) FITC-goat anti-rabbit
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
